Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open Label, Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

Next Previous
Search
Trial Profile

A Multicenter, Open Label, Phase II Basket Trial Exploring the Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors

Status: Suspended
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Rucaparib (Primary)
  • Indications Adenocarcinoma; Bladder cancer; Carcinoma; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Prostate cancer; Renal cell carcinoma; Urogenital cancer
  • Focus Therapeutic Use
  • Acronyms ARIANES

    • Most Recent Events

    • 25 Mar 2024 Planned primary completion date changed from 1 Apr 2024 to 1 Dec 2024.
    • 19 Jan 2023 Status changed from recruiting to suspended.
    • 13 Sep 2022 Results of platinum-sensitive metastatic urothelial cancer (mUC) and metastatic castration-resistant prostate cancer cohorts, presented at the 47th European Society for Medical Oncology Congress.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top